LICENSE: This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.


9607835
20545
Mol Psychiatry
Molecular psychiatry
1359-4184
1476-5578

30733594
6685773
10.1038/s41380-019-0364-x
NIHMS1519504
Article
Full recovery of the Alzheimer’s disease phenotype by gain of function of Vacuolar Protein Sorting 35
Li Jian-Guo
Chiu Jin
Praticò Domenico
Alzheimer’s Center at Temple, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140
Authors’ contributions

J-GL and DP designed the study; J-GL and JC performed the experiments; J-GL and DP analyzed the data and drafted the manuscript. All authors have discussed the results and seen the final version of the paper before submission.

Correspondence to: Domenico Praticò, MD, Scott Richards North Star Foundation Chair, Alzheimer’s Research, Alzheimer’s Center at Temple, 1160, Medical Education and Research Building, 3500 North Broad Street, Philadelphia, PA 19140, praticod@temple.edu, Telephone: 215-707-9380, Fax: 215-707-9890
24 1 2019
07 2 2019
10 2020
07 8 2019
25 10 26302640
This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.
Deficit in retromer complex function secondary to lower levels of one of its major components, the vacuolar protein sorting 35 (VPS35), has been reported in Alzheimer’s disease (AD) brains. VPS35 genetic reduction results in increased Aβ levels and synaptic pathology in mouse models of the disease. However, whether restoration of its levels has an effect on the AD-like phenotype which includes Aβ plaques, tau tangles and memory impairments remains unknown. In this paper, we investigated the effect of VPS35 gene delivery into the central nervous system on the development of the neuropathology and behavioral deficits of the triple transgenic (3xTg) mice. Compared with controls, animals over-expressing VPS35 had an amelioration of spatial learning and working memory, which associated with a significant reduction in Aβ levels and deposition and tau phosphorylation. Additionally, the same animals had a significant improvement of synaptic pathology and neuroinflammation. In vitro study confirmed that VPS35 up-regulation by reducing total levels of APP and tau results in a significant decrease in their metabolic products and phosphorylated isoforms, respectively. Our results demonstrate for the first time that VPS35 is directly involved in the development of AD-like phenotype, and for this reason should be considered as a novel therapeutic target for AD.


Introduction

Aging is the strongest risk factor for Alzheimer’s disease (AD), the most common of dementia worldwide which is characterized by a complex pathogenesis and for which unifying mechanisms have been widely investigated by research labs in the field [1,2]. Loss of protein homeostasis is one common feature of the majority of aging organisms, and increasing evidence indicates that alteration in cell systems responsible for protein sorting and trafficking such as the vacuolar protein sorting system, aka retromer complex, may contribute to neurodegeneration in the AD brains by interfering with the removal of the disease-related specific pathologic proteins (i.e., Aβ and hyper-phosphorylated tau) [3–5]. Interestingly, consistent data in the literature show that the development of retromer dysfunction-dependent neuropathology is always secondary to a partial “loss of function” of this system. Thus, deficiency in the complex function resulting from down-regulation of one of its major components, VPS35, has been reported in hippocampi of AD patients; and genetic studies found that its variants increase the risk of developing AD [6,7]. On the other hand, VPS35 genetic reduction results in an increase of Aβ levels, cognitive impairments and synaptic dysfunction in a mouse model of AD-like amyloidosis [8, 9]. Recently, we have assessed the expression of VPS35 and other components of the retromer recognition core in the brains of the Tg2576 mice and reported an age-dependent decrease in the steady state levels of these proteins in the cortex but not in the cerebellum, an area known to be avoided of any AD-like pathology [10].

Taken together, all these studies clearly support the hypothesis that VPS35 is an active player and functionally involved in AD pathogenesis. However, whether restoration of its levels or a more general “gain of function” of the retromer complex system has an effect in vivo on part of the full AD-like phenotype is completely unknown. To test this hypothesis, in the current study we assessed the effect of VPS35 over-expression in the brains of 3xTg mice which are known to develop Aβ plaques, tau tangles and memory impairments.

Material and Methods

Injection of AAV-VPS35 into Neonatal Mice

3xTg mice harboring a human mutant PS1 (M146V) knock-in, and mutant amyloid precursor protein (APP; KM670/671NL) and tau (P301L) transgenes, and 3xTg wild‐type (WT) are the animals used in this study. The AAV‐VPS35 with a specific neuronal promoter (synpasin-1) and the AAV-empty vector were purchased from a commercial vendor (Vector Biosystems Inc., Malvern, PA). The injection procedures were performed as described previously [11, 12, 13]. Briefly, 2μl (3.5 × 1013 genome particles/ml) were bilaterally injected into the cerebral ventricle of newborn mice using a 10μl Hamilton syringe. A total of 41 pups were used for the study, ten WT and ten 3xTg mice were injected with AAV‐ VPS35; whereas eleven WT and ten 3xTg mice were injected with empty vector (Ctrl). Animals were then followed until they were 12 months old, when they first underwent behavioral testing, and two weeks later euthanized. All animal procedures were approved by the Institutional Animal Care and Usage Committee, in accordance with the U.S. National Institutes of Health guidelines.

Behavioral Tests

All animals were pre-handled for 3 days prior to testing. They were tested in a randomized order, and all tests were conducted by an experimenter blinded to the treatment or genotype.

Y‐Maze

The Y‐maze apparatus consisted of 3 arms 32cm long × 10cm wide with 26cm walls (San Diego Instruments, San Diego, CA). Testing was always performed in the same room and at the same time to ensure environmental consistency, as previously described [14, 15].

Morris water maze

To perform the Morris water maze, we used a white circular plastic tank (122 cm in diameter, walls 76 cm high), filled with water maintained at 22°±2°C, and made opaque by the addition of a nontoxic white paint, as previously described [14,15]. Briefly, mice were trained for four consecutive days to find a Plexiglas platform submerged in water from four different starting points. Mice were assessed in the probe trial, which consisted of a free swim lasting for 60 s without the platform, 24 h after the last training session. Animals’ performances were monitored using Any‐Maze™ Video Tracking System (Stoelting Co., Wood Dale, IL).

Immunoblot Analyses

Primary antibodies used in this paper are summarized in the Table. Proteins were extracted in enzyme immunoassay buffer containing 250mM Tris base, 750mM NaCl, 5% NP‐40, 25mM EDTA, 2.5% sodium deoxycholate, 0.5% sodium dodecyl sulfate, and an EDTA‐free protease and phosphatase inhibitors cocktail tablet (Roche Applied Science, Indianapolis, IN), sonicated, and centrifuged at 45,000 rpm for 45 minutes at 4°C, and supernatants were used for immunoblot analysis, as previously described [16–18]. Briefly, total protein concentration was determined by using a BCA Protein Assay Kit (Pierce, Rockford, IL), samples were electrophoretically separated according to the molecular weight of the target molecule, and then transferred onto nitrocellulose membranes (Bio‐Rad). They were blocked with Odyssey blocking buffer for 1 hour, and then incubated with primary antibodies overnight at 4°C. After 3 washing cycles with T‐TBS, membranes were incubated with IRDye 800CW‐ or IRDye 680CW‐labeled secondary antibodies (LI‐COR Bioscience, Lincoln, NE) at 22°C for 1 hour. Signals were developed with Odyssey Infrared Imaging Systems (LI‐COR Bioscience). Actin was always used as an internal loading control.

Biochemical Analyses

Mouse brain homogenates were sequentially extracted first in radioimmunoprecipitation assay (RIPA) for the Aβ 1–40 and 1–42 soluble fractions, then in formic acid for the Aβ 1–40 and 1–42 insoluble fractions, and then assayed by a sensitive sandwich enzyme‐linked immunosorbent assay (ELISA) kit (Wako Chemicals, Richmond, VA) as previously described [16–18]. The assay for measuring the insoluble sarkosyl-soluble tau fraction was performed as previously described [16–18].

Immunohistochemistry

Primary antibodies used are summarized in the Table. Immunostaining was performed as reported previously by our group [16–18]. Briefly, serial coronal sections were mounted on 3‐aminopropyl triethoxysilane‐coated slides. Every eighth section from the habenular to the posterior commissure (8–10 sections per animal) was examined using unbiased stereological principles. The sections for testing Aβ (4G8 antibody) were deparaffinized, hydrated, and pretreated with formic acid (88%) and subsequently with 3% H2O2 in methanol. The sections for testing total tau (HT7 antibody), and phospho‐tau epitopes, were deparaffinized, hydrated, subsequently pretreated with 3% H2O2 in methanol, and then treated with citrate (10mM) or IHC‐Tek Epitope Retrieval Solution (IHC World, Woodstock, MD) for antigen retrieval. Sections were blocked in 2% fetal bovine serum before incubation with primary antibody overnight at 4°C. Next, sections were incubated with biotinylated anti‐mouse immunoglobulin G (Vector Laboratories, Burlingame, CA) and then developed by using the avidin‐biotin complex method (Vector Laboratories) with 3,3′‐diaminobenzidine as a chromogen. Light microscopic images were used to calculate the area occupied by the immunoreactivities by using the software Image‐Pro Plus for Windows version 5.0 (Media Cybernetics, Bethesda, MD).

Thioflavin-S Staining.

The staining was performed as previously described [19]. Briefly, brain sections were deparaffinized and hydrated with the clearing agent xylene and a series of grade ethanol. After washed 3 times with PBS, the brain sections were incubated in filtered 1% Thioflavin S (Sigma-Aldrich, St. Louis, MO) for 8 minutes at room temperature. The tissues were washed twice in 70% ethanol, washed in PBS and mounted under a coverslip with anti-fading mounting media. The images were captured using the Nikon TiE fluorescent microscope (Nikon Instruments Inc., Melville, NY).

Real-Time quantitative reverse transcription-PCR amplification

RNA was extracted and purified using RNeasy mini kit (Qiagen, Valencia, CA), as previously described [20, 21]. Briefly, 1μg of total RNA was used to synthesize cDNA in a 20μl reaction using the RT2 First Strand Kit for RT-PCR (SuperArray Bioscience, Frederick, MD). Human APP and Tau genes were amplified by using the proper primers obtained from Super-Array Bioscience (Valencia, CA), and β-actin was always used as an internal control gene to normalize for the amount of RNA. Quantitative real-time RT-PCR was performed by using StepOnePlus Real-Time PCR Systems (Applied Biosystems, Foster City, CA). One microliter of cDNA was added to 10μl of SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). Each sample was run in triplicate, and analysis of relative gene expression was done by StepOne software v2.1.

Cells and treatment

Neuro-2 A neuroblastoma (N2A) cells stably expressing human APP carrying the K670 N, M671L Swedish mutation (N2A-APPswe) were cultured in Dulbecco’s modified Eagle medium supplemented with 10% fetal bovine serum, 100 U/mL streptomycin (Cellgro, Herdon, VA) and 400 mg/mL G418 (Invitrogen, Carlsbad, CA) at 37°C in the presence of 5% CO2. The cells were cultured to 80% to 90% confluence in six-well plates and then transfected with VPS35 plasmid (Addgene, Cambridge, MA), as previously described [20]. After 48 hrs transfection, media were collected for Aβ 1–40 measurement and cell lysates harvested after treatment with RIPA buffer for Western blotting analyses. Immunofluorescence studies were performed as previously described [21]. Briefly, N2A-APPswe cells transient transfected with control vector and VPS35 plasmid were plated on glass cover slips and the following day fixed in 4% paraformaldehyde for 15 min at RT. After rinsing 3 times with PBS, cells were incubated in a blocking solution (3% normal serum / 0.1 % TX-100) for 10 min at RT and then with the primary antibody against VPS35 for 1 hour at room temperature. After 3 times washings with PBS, cells were incubated for 1 h with a secondary Alexa 448- conjugated antibody. Cover slips were mounted using VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA) and analyzed with an Olympus BX60 fluorescent microscope (Olympus, Center Valley, PA). To control for cell viability after transfection, we always assayed for levels of LDH release in the supernatant collected at the end of the transfection. No differences in the levels of LDH between control and transfected cells were observed under our experimental condition (data not shown).

Data Analysis

One‐way analysis of variance and then Bonferroni multiple comparison tests were performed using Prism 5.0 (GraphPad Software, La Jolla, CA). All data are always presented as mean ± standard error of the mean. Significance was set at p &lt; 0.05.

Results

VPS35 gene transfer ameliorates cognition in 3xTg mice.

To assess the effect of VPS35 gene transfer on behavioral responses, mice were initially tested in the Y-maze paradigm. First, we observed that there was no difference in the general motor activities among the four groups of mice and between the ones receiving empty vector or treated with AAV-VPS35, as we found that the total number of arm entries was not different (Figure 1A). On the other hand, we observed that compared with wild type mice (WT), 3xTg had a significant reduction in the percentage of alternations, which was rescued in the 3xTg mice receiving the AAV-VPS35 (Figure 1B). Next, mice underwent the Morris water maze testing paradigm, which involve a visible platform training followed by hidden platform testing with four probe trials per day. During the four days training of the test, no differences were observed among the four groups and all mice in each group reached the training criterion and were proficient swimmers. By contrast, in the probe trial compared with WT the 3xTg mice had a reduction in the number of entries to platform, and the time spent in the platform quadrant, but an increase in the latency to the first entry to the platform, which were improved in the 3xTg receiving the AAV-VPS35 (Figure 1C–E). Finally, although compared with WT the 3xTg mice spent more time in the opposite quadrant and the treatment partially reduced this measure, the results never reached a statistical significant difference (Figure 1F). No differences for both tests were observed when males and females were analyzed separately (data not shown). No significant effects for both paradigms were observed in the WT mice receiving the AAV-VPS35 treatment (Figure 1A–F).

VPS35 gene transfer decreases brain Aβ levels and deposition

Mice were euthanized two weeks after the behavioral testing, and brains assayed first of all for the expression levels of the product of the gene that was transferred. As shown in figure 2, compared with 3xTg mice receiving empty vector the ones treated with AAV-VPS35 had a significant increase in the steady state level of the protein. Histochemical analysis of brain sections from the same mice confirmed a higher immune-reactivity for this protein in the treated mice (Figure 2C,D). Coincidental with this increase we observed that also the other protein component of the retromer recognition core, VPS26b, but not VPS29, was significantly increased (Figure 2A, B).

Next, we investigated the effect of VPS35 over-expression on the AD-like amyloidotic aspect of the phenotype of this model by assessing Aβ/APP levels and metabolism. Compared with 3xTg controls, mice treated with AAV-VPS35 had a significant reduction of Aβ 1–40 and Aβ1–42 in both the RIPA-soluble as well as the formic acid-soluble fraction of these peptides (Figure 3 A, B). Confirming these data, we observed that Aβ immuno-reactive areas and the Thioflavin-S positive areas in the brains of the same animals were also significantly decreased when compared with 3xTg controls (Figure 3 C–E). Because we observed those changes in Aβ peptides levels, next we investigated the metabolism of its precursor protein, APP, in an attempt to identify potential mechanisms responsible for this effect. To this end, we assessed levels of APP, α-secretase (ADAM10), β-secretase (BACE1) and the four components of the γ-secretase complex by western blot analysis. Compared with controls, 3xTg receiving the AAV-VPS35 had a significant reduction in the steady state levels of APP, sAPPα and sAPPβ (Figure 3 F,G). By contrast, we did not observe any significant changes in the level of ADAM10, BACE1 and the four components of the γ-secretase complex, PS1, Nicastrin, Pen 2, and APH1, between the two groups of mice (Figure 3 F, G). Since we observed a reduction in APP at the protein levels, we also assessed its mRNA levels, which, as shown in figure 3G, were not different between the two groups of mice (Figure 3 H).

VPS35 brain over-expression affects tau phosphorylation

Next, we evaluated the effect of brain VPS35 over-expression on total tau levels and its phosphorylation at different epitopes in the two groups of mice. As shown in figure 4, we observed that levels of total soluble tau protein were significantly reduced in the 3xTg mice over-expressing VPS35. Interestingly, this was also the case when the levels of sarkosyl-soluble tau fraction (the insoluble fraction) was assessed (Figure 4 A,B). In addition, compared with controls, mice over-expressing VPS35 had a significant decrease in tau phosphorylated at epitopes Ser2020/Thr205, Thr181, Ser396/Ser404, Ser396, as respectively recognized by the AT8, AT270, PHF1, and PHF13 antibodies, but not changes were observed for tau phosphorylated at epitope Thr231and, as recognized by the AT180 antibody (Figure 4 A,B). Histochemical staining analyses confirmed a decrease in the immune-reactivity for total tau and the same phosphorylated tau epitopes in brain sections of mice over-expressing VPS35 when compared with controls (Figure 4 D,E). Since we observed a decrease in total tau at the protein levels, we also assessed its mRNA levels, which, as shown in figure 4C, were not different between the two groups of mice (Figure 4C).

VPS35 brain overexpression modulates synaptic integrity and neuroinflammation

It is known that the memory impairments the AD-like phenotype is typically associated with altered markers of synaptic proteins. For this reason, next we investigated whether VPS35 gene transfer had any effect on it. Compared with controls, 3xTg overexpressing VPS35 had a significant elevation in the steady state levels of synaptophysin (SYP), which was confirmed by immunohistochemistry analysis (Figure 5 A–D). By contrast, no significant differences between the two groups were observed for post-synaptic density protein-95 (PSD-95) and the microtubule associated protein 2 (MAP2) (Figure 5A, B). Finally, compared with controls 3xTg, mice over-expressing VPS35 had a statistically significant decrease in the steady state level of GFAP, a marker of astrocytes activation, which was also confirmed by immunohistochemistry analyses (Figure 5 E–H). However, no significant differences were observed between the two groups when the steady state levels of Iba1, a marker of microglia cells activation, were assessed (Figure 5 E, F).

In Vitro Study: VPS35 effects on Aβ formation and APP processing

To further confirm the effect of VPS35 on Aβ formation and APP metabolism, we transfected the N2A-APPswe cells with VPS35 plasmid for 48 hrs, supernatants collected and assayed for Aβ 1–40, while cells lysates used for Western blot analyses. Compared with controls, we observed that the neuroblastoma cells transfected with VPS35 had a significant increase in steady state levels of VPS35 and VPS26b, but not VPS29 (Figure 6A, B). The increase in VPS35 was also confirmed by immunofluorescence analyses (Figure 6C). As shown in Figure 6D, we found that compared with vehicle controls, conditioned media from cell over-expressing VPS35 had significantly lower Aβ 1–40 peptide levels. In addition, we observed that the over-expression of VPS35 was accompanied by a significant decrease in the steady state levels of APP, sAPPα and sAPPβ (Figure 6 E, F).

Discussion

In the current study we show for the first time that over-expression of VPS35, the main component of the retromer recognition core, in the central nervous system (CNS) of the 3xTg mice rescues their behavioral deficits, results in a significant reduction of the Aβ and tau neuropathology, lowers neuroinflammation and ameliorates synaptic pathology.

The retromer system is a highly conserved multimeric protein complex present in all eukaryotic cells whose activity is essential for regulating the recycling and retrieval of several protein cargos from the endosome to the trans-Golgi network or the cell surface [22, 23]. In recent years, molecular and genomic studies have provided strong evidence that aberrant regulation of endosomal protein sorting and trafficking secondary to a dysfunction of the retromer complex system is implicated in the pathogenesis of several neurodegenerative diseases [24, 25]. From a structural point of view, the retromer complex is a multi-modular protein assembly, in which each module can vary depending on the specific function. However, the different modules are unified by having the same cargo recognition core formed by three main VPS proteins: VPS35, VPS26 and VPS29 and a membrane–targeting dimer of the sortin nexin which binds and transports different cargos [26]. Today, we know that VPS35 is the single most critical protein of the whole retromer assembly, and indeed knocking down VPS35 is sufficient to cause retromer complex dysfunction. Importantly, previous studies have shown that lower levels of VPS35 can ultimately affect the formation of the complex by influencing expression of the other two retromer core proteins (VPS29 and VPS26) suggesting a loss of stability of the complex as a functional unity [27].

The first implication of the complex in AD pathogenesis originated form a molecular profiling study showing that VPS35 and VPS26 were significantly down-regulated in the hippocampi of patients with late-onset of the disease. Later, it was reported that retromer deficiency associates with some of the disease processes since VPS35 deficient mice have cognitive deficits, synaptic dysfunction and higher Aβ levels. However, a strong biologic link between retromer dysfunction and AD was provided by human genetic studies showing that variants of genes encoding for VPS35 significantly increase the risk to develop the disease [28]. Intriguingly, analysis of all the literature available so far consistently demonstrates that retromer/VPS35-dependent pathology typically derives from a reduction or partial loss and not a gain of function of this complex [25]. To this end, whether up-regulating or restoring its levels in the CNS have any direct biological effect on the pathophysiology of AD remains unknown.

To fill this gap, we implemented a genetic approach aimed at over-expressing VPS35 in the CNS of the 3xTg mice, which develop Aβ and tau neuropathology together with behavioral deficits. First, we demonstrated that VPS35 gene transfer had the effect of rescuing working memory in the 3xTg mice, as shown in the Y-maze, which measure spontaneous alternation of rodents once placed in the maze [29]. Thus, while as expected 3xTg controls had less alternation that the WT mice, the 3xTg mice receiving the VPS35 gene had a significant improvement of this measure, which was undistinguishable from WT. These changes could not be ascribed to an alteration of the general motor activities secondary to the injection or the treatment since no differences were observed among the four groups of mice when the number of entries in each arm of the maze was assessed. In addition, the same treatment resulted in a significant amelioration of their spatial learning and memory as documented in the Morris water maze [30]. Thus, in the probe trial compared with WT the 3xTg mice receiving empty vector had a lower number of platform entry and time spent in the platform zone together with an increase in the latency to first entry, and all of these parameters were improved in the 3xTg mice receiving the AAV-VPS35.

Consistent with the efficacy of our experimental protocol, we observed that indeed the steady state levels of VPS35 protein were significantly up-regulated in the brains of mice receiving the active treatment even after 12 months. This result was in accordance with our previous studies in which we implemented a similar gene transfer approach [11–13]. Over-expression of VPS35 in the brains of the 3xTg mice manifested with a significant reduction of Aβ peptides levels both in the RIPA- and formic acid-soluble fractions, which was also reflected by a significant decrease in the amount of Aβ immuno-reactive deposits as assessed by measuring the brain amyloid burden. These deposits were thioflavin-S positive, which were also reduced after the treatment. Having observed those significant changes in amyloidosis, next we assessed the effect of the treatment on the metabolic processing of APP. While we did not find any changes in the levels of the major proteases involved in its cleavage, we observed that mice over-expressing VPS35 had a significant reduction in the steady state levels of APP which was associated with a similar decrease in sAPPα and sAPPβ. Interestingly no changes were observed for the mRNA levels of APP, suggesting a post-translational regulation of APP secondary to VPS35 over-expression. Importantly, by using neuronal cell lines stably expressing the human APP Swedish mutant we were able to reproduce the same results in terms of Aβ formation and APP metabolism after transient transfection with VPS35 plasmid. Taken together these findings support the hypothesis that restoration of the retroer complex system function resulted in decreased time spent by the APP in the endosome and therefore in less time for its own proteolytic processing and generation of Aβ peptides.

Accumulation of highly phosphorylated tau protein and formation of intracellular fibrillary tangles is the second most common feature of AD neuropathology. For this reason, next we investigated the effect of the treatment on this aspect of the phenotype. Compared with 3xTg mice controls, we observed that VPS35 brain over-expression resulted in a significant decrease in total soluble tau, its insoluble fraction and tau phosphorylation levels at specific epitopes [31].

Since learning and memory tasks are known to be directly modulated not only by the amount of tau pathology but also by synaptic integrity, we measured the levels of some important synaptic proteins. Compared with control 3xTg mice, we found that VPS35 brain over-expression resulted in a significant elevation in the levels of synaptophysin, a marker of pre-synaptic protein integrity, underscoring the biochemical substrate for the behavioral amelioration we initially observed in the treated mice [32, 33]. Having found significant effect of our treatment on behavior, neuropathology and synapse, next we wanted to assess whether VPS35 gene transfer also affected neuroinflammatory responses. In this regard, we assayed the levels of two markers of inflammatory cells activation, GFAP for astrocytes and Iba1 for microglia, which have been reported to be elevated in AD reflecting dysregulated inflammatory reactions [34–37]. Under our experimental condition and coincidental with the lowering effect observed for bot Aβ and tau neuropathology we observed that compared with controls, brains from mice over-expressing VPS35 had a significant reduction in astrocyte activation.

In summary, our study is the first demonstration that restoration of VPS35 levels and function directly rescue the AD-like phenotype of a mouse model with learning and memory impairments, Aβ deposits, and tau neurofibrillary tangles. Collectively, the findings presented in our paper further support an important functional role of the retromer recognition core which by modulating APP levels and its metabolic fate can ultimately ameliorates the AD-associated behavioral deficits, synaptic integrity and neuroinflammation. We conclude that VPS35 should be considered as a potentially promising therapeutic target for AD treatment. It is of great interest to note that, since there are reports showing an association of VPS35 mutations with the development of Parkinson’s disease (PD) [38], our results would have much broader clinical and translational implications. Thus, one could envision a scenario where restoring VPS35 levels would be beneficial not only for AD but also for PD.

Additionally, small pharmacologic chaperones have been recently identified and characterized as novel compounds that selectively bind and stabilize the retromer complex and by doing so increase VPS35 levels in hippocampal neurons [39]. This fact together with our findings let us speculate that we are now well positioned from a therapeutic point of view to target VPS35 with a pharmacological probe in vivo. This approach would be certainly a departure from the current ones aiming at enzyme(s) directly responsible for Aβ biosynthesis, since it would target a common cellular mechanism (i.e., protein sorting and trafficking) which is widely considered at the core of AD pathogenesis.

Acknowledgments

Domenico Praticò is the Scott Richards North Star Charitable Foundation Chair for Alzheimer’s Research. This study was supported in part by grants from the National Institute of Health (AG056689, AG055707), and the Scott Richards North Star Charitable Foundation.

Figure 1. VPS35 gene transfer rescues behavioral deficits of 3xTg mice.

(A) Number of total arm entries for 3xTg mice (3xTg) and wild‐type mice (WT) treated with AAV‐VPS35 (VPS35) or AAV‐empty vector control (Ctrl). (B) Percentage of alternations between 3xTg and WT mice receiving AAV‐VPS35 or AAV‐empty vector (*p&lt;0.05). (C) Morris water maze, probe trial for the same four groups of mice, number of entries to the platform area; (D) latency to first entry to the platform area; (E) time spent in the platform quadrant; (F) time spent in the opposite quadrant. Values represent mean ± standard error of the mean (*p&lt;0.05). (WT-Ctrl: n=11; WT‐VPS35: n =10; 3xTg-Ctrl, n=8; 3xTg-VPS35, n=8).

Figure 2. Brain VPS35 overexpression modulates retromer recognition core levels in the 3xTg mice.

(A) Representative western blot analysis of VPS35, VPS26b, VPS29 proteins in brain cortex homogenates from 3xTg mice receiving AAV-VPS35 (VPS35) or empty vector control (Ctrl). (B) Densitometry of the immunoreactivities shown in the previous panel (*p&lt;0.05, n=6). (C). Representative images of brain cortex sections from mice receiving AAV-VPS35 (VPS35) or empty vector (Ctrl) immuno-stained with VPS35 antibody (scale bar: 100μm). (D) Quantification of the integrated optical density for the immunoreactivity to the same antibody shown in panel C. Values represent mean ± standard error of the mean (*p&lt;0.05).

Figure 3. Brain VPS35 overexpression lowers Aβ peptides levels and deposition in the 3xTg mice.

(A, B) Radioimmunoprecipitation assay (RIPA)‐soluble and formic acid (FA)‐extractable Aβ1‐40 and Aβ1‐42 levels in cortex of 3xTg mice receiving empty vector (Ctrl) or AAV-VPS35 (VPS35) were measured by sandwich enzyme‐linked immunosorbent assay (*p&lt;0.05, Ctrl, n=8; VPS35, n=8). (C) Representative images of brain sections from mice receiving AAV-VPS35 (VPS35) or empty vector (Ctrl) stained with Thioflavin-S. (D) Representative images of brain sections from mice receiving AAV-VPS35 (VPS35) or empty vector (3xTg) immuno-stained with 4G8 antibody to detect Aβ immunoreactivity (scale bar: 500 μm). (E) Quantification of the area occupied by Aβ immunoreactivity in brains from mice receiving AAV-VPS35 (VPS35) or empty vector (3xTg) (*p&lt;0.05). (F) Representative Western blots of amyloid precursor protein (APP), sAPPα, sAPPβ, BACE1, ADAM‐10, APH‐1, Nicastrin, Pen‐2, and PS1 in cortex homogenates from 3xTg mice receiving AAV-VPS35 (VPS35) or empty vector (Ctrl). (G) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel (*p&lt;0.05). (H) APP mRNA levels measured by RT-PCR in brain cortex from 3xTg mice receiving AAV-VPS35 (VPS35) or empty vector (Ctrl). Values represent mean ± standard error of the mean (Ctrl, n=6; VPS35, n=6).

Figure 4. Brain VPS35 overexpression reduces tau phosphorylation and pathology in the 3xTg mice.

(A) Representative Western blots of total soluble tau (HT7), insoluble tau (HT7), and phosphorylated tau at residues Ser202/Thr205 (AT8), Thr231/Ser235 (AT180), Thr181 (AT270), Ser396/Ser404 (PHF1), and Ser396 (PHF13) in brain cortex homogenates from 3xTg mice receiving empty vector (Ctrl) or AAV‐VPS35 (VPS35). (B) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel (*p&lt;0.05, n=6). (C) Tau mRNA levels measured by RT-PCR in brain cortex from 3xTg mice receiving AAV-VPS35 (VPS35) or empty vector (Ctrl). (D) Representative immuno-histochemical staining images for HT7, AT270 and PHF13 positive areas in brain sections of 3xTg mice receiving empty vector control (Ctrl) or AAV‐VPS35 (VPS35) (scale bar: 100 μm). (E) Quantification of the integrated optical density for the immunoreactivity to the same antibody shown in the previous panel (*p&lt;0.05). Values represent mean ± standard error of the mean (Ctrl, n=6; VPS35, n=6).

Figure 5. Brain overexpression of VPS35 affects synaptic integrity and neuroinflammation in the 3xTg mice.

(A) Representative western blot analysis of synaptophysin (SYP), post-synaptic density-95 (PSD-95), microtubule associated protein2 (MAP2) in brain cortex homogenates from 3xTg mice receiving empty vector (Ctrl) or AAV-VPS35 (VPS35). (B) Densitometric analyses of the immunoreactivities presented in the previous panel (*p&lt;0.05). (C) Representative images of brain sections from mice receiving AAV-VPS35 (VPS35) or empty vector (3xTg) immuno-stained with SYP antibody (scale bar: 100 μm). (D) Quantification of the integrated optical density for the immunoreactivity to the same antibody shown in panel C (*p&lt;0.05). (E) Representative Western blot analyses of glial fibrillary acidic protein (GFAP) and Iba1 in brain cortex homogenates from 3xTg mice receiving empty vector (Ctrl) or AAV-VPS35 (VPS35). (F) Densitometric analyses of the immunoreactivities presented in the previous panel (*p&lt;0.05). (G) Representative images of brain sections from mice receiving AAV-VPS35 (VPS35) or empty vector (3xTg) immuno-stained with GFAP antibody (scale bar: 100 μm). (H) Quantification of the integrated optical density for the immunoreactivity to the same antibody shown in the previous panel (*p&lt;0.05). Values represent mean ± standard error of the mean (Ctrl: n=6; VPS35, n=6).

Figure 6. Over-expression of VPS35 in N2A-APPswe cells affects Aβ formation and tau phosphorylation.

(A) Representative western blot analysis of VPS35, VPS26b, VPS29 proteins in N2A-APPswe cells transfected with VPS35 plasmid (VPS35) or vector control (Ctrl). (B) Densitometry of the immunoreactivities shown in the previous panel (*p&lt;0.05, n=6). (C) Representative images of immunofluorescence analysis of cells transiently transfected with VPS35 cDNA and incubated with primary antibody for VPS35 (green). (D) Aβ1‐40 levels in conditioned media from cell transfected with empty vector (Ctrl) or VPS35 plasmid (VPS35) were measured by sandwich enzyme‐linked immunosorbent assay (*p&lt;0.05, Ctrl, n=6; VPS35, n=6). (E) Representative Western blots of amyloid precursor protein (APP), sAPPα and sAPPβ in N2A-APPswe cells transfected with VPS35 plasmid (VPS35) or vector control (Ctrl). (F) Densitometric analyses of the immunoreactivities to the antibodies shown in the previous panel. Values represent mean ± standard error of the mean (Ctrl: n=6; VPS35, n=6; *p&lt;0.05).

Table 1. Antibodies used in the study.

Antibody	Host	Application	Source	Catalog Number	
4G8	Mouse	IHC	Covance	SIG-39220	
ADAM10	Rabbit	WB	Millipore	AB19026	
APH1	Rabbit	WB	Millipore	AB9214	
APP	Mouse	WB	Millipore	MAB348	
BACE1	Rabbit	WB	IBL	18711	
GFAP	Mouse	WB, IHC	Santa Cruz	sc-33673	
HT7	Mouse	WB, IHC	Thermo	MN1000	
Iba1	Mouse	WB	Santa Cruz	sc-32725	
MAP2	Rabbit	WB	Millipore	AB5622	
Nicastrin	Rabbit	WB	Cell Signaling	3632	
Pen2	Rabbit	WB	Invitrogen	36–7100	
PHF1	Mouse	WB	Dr. P. Davies	Gift	
PHF13	Mouse	WB, IHC	Cell Signaling	9632	
PS1	Rabbit	WB	Cell Signaling	3622S	
PSD95	Mouse	WB	Thermo	MA1–045	
sAPPα	Mouse	WB	IBL	11088	
sAPPβ	Mouse	WB	IBL	10321	
SYP	Mouse	WB, IHC	Santa Cruz	sc-12737	
VPS26b	Rabbit	WB	Proteintech	15915–1-AP	
VPS29	Goat	WB	AbCam	ab10160	
VPS35	Goat	WB, IHC, IF	AbCam	ab10099	
β-Actin	Mouse	WB	Santa Cruz	sc-47778	
WB: Western blot; IHC: Immunohistochemistry; IF: Immunofluorescence

Conflict of interest

The authors have no conflicting financial interest to disclose.


References

1. Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimer Dement 2017; 2017 ; 325–373.
2. Giannopoulos PG , Praticò D . 2015 Alzheimer’s disease In: Diet and Nutrition in Dementia and Cognitive Decline. Eds. Martin Colin R. and Reddy Victor . Elsevier Publisher, London UK; pp. 13–21.
3. Vilchez D , Saez I , Dillin A . The role of protein clearance mechanisms in organismal ageing and age-related diseases. Nature Commun 2014; 8 ; 5 :5659.
4. Yerbury JJ , Ooi L , Dillin A , Saunders DN , Hatters DM , Beart PM , Cashman NR , Wilson MR , Ecroyd H . Walking the tightrope: proteostasis and neurodegenerative disease. J. Neurochem 2016; 137 (4 ):489–505.26872075
5. Wang X , Huang T , Bu G , Xu H . Dysregulation of protein trafficking in neurodegeneration. Mol. Neurodegen 2014; 9 :31.
6. Small SA , Kent K , Pierce A , Leung C , Kang MS , Okada H , Honing L , Vonsattel JP , Kim TW . Model-guided microarray implicates the retromer complex in Alzheimer’s disease. Ann. Neurol 2005; 58 :909–919.16315276
7. Vardarajan BN , Bruesegem SY , Harbour ME , Inzelberg R , Friedland R . St George-Hyslop P , Identification of Alzheimer’s disease-associated variants in genes that regulate retromer function. Neurobiol. Aging 2012; 33 (9 ):2231.e15–2231.e30. doi: 10.1016/j.neurobiolaging.2012.04.020 .
8. Muhammad A , Flores I , Zhang H , Yu R , Staniszewski A , Planel E , Hernan M , Ho L , Kreber R , Honig LS , Ganetzky B , Duff K , Arancio O , Small SA . Retromer deficiency observed in Alzheimer’s disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. USA 2008; 105 ; 7327–7332.18480253
9. Wen L , Tang F-L , Hong Y , VPS35 aplo-insufficiency increases Alzheimer’s disease neuropathology. J. Cell Biol 2011; 195 ; 765–779.22105352
10. Chu J , Praticò D . The retromer complex system in a transgenic mouse model of AD: influence of age. Neurobiol. Aging 2017; 52 : 32–38.28110103
11. Chu J , Giannopoulos PF , Ceballos-Diaz C , Golde TE , Praticò D . Adeno-associated virus-mediated brain delivery of 5-Lipoxygenase modulates the AD-like phenotype of APP mice. Mol. Neurodegen 2012; 7 :1.
12. Chu J , Giannopoulos PF , Ceballos-Diaz C , Golde TE , Praticò D . 5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer disease. Ann. Neurol 2012; 72 : 442–454.23034916
13. Li JG , Chu J , Praticò D . Downregulation of autophagy by 12/15Lipoxygenase worsens the phenotype of an Alzheimer’s disease mouse model with plaques, tangles, and memory impairments. Mol Psychiatry 2018 10 2. doi: 10.1038/s41380-018-0268-1 . [
14. Lauretti E , Iuliano L , Praticò D . Extra-virgin olive oil ameliorates cognition and neuropathology of the 3xTg mice: role of autophagy. Ann. Clin. Transl. Neurol 2017; 4 (8 ):564–574.28812046
15. Li J-G , Barrero C , Merali S , Praticò D . Genetic absence of ALOX5 protects from homocysteine-induced memory impairment, tau phosphorylation and synaptic pathology. Hum. Mol. Genet 2017; 26 (10 ):1855–1862.28334897
16. Giannopoulos PF , Chu J , Sperow M , Li JG , Yu WH , Kirby LG , Abood M , Praticò D . Pharmacologic inhibition of 5-Lipoxygenase improves memory, rescues synaptic dysfunction, and ameliorates tau pathology in a transgenic model of tauopathy. Biol. Psychiatry 2015; 78 : 693–701.25802082
17. Di Meco A , Joshi YB , Lauretti, E, Praticò, D. Maternal dexamethasone exposure ameliorates cognition and tau pathology in the offspring of triple transgenic AD mice. Mol. Psychiatry 2016; 21 (3 ):403–410.26077691
18. Vagnozzi AN , Giannopoulos PF , Praticò D . The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy. Transl. Psychiatry 2017; 7 (12 ):1288.29249809
19. Li J-G , Praticò D . High levels of homocysteine results in cerebral amyloid angiopathy in mice. J Alzheimers Dis 2015; 43 (1 ): 29–35.25061050
20. Li J-G , Barrero C , Gupta S , Kruger WD , Merali S , Praticò D . Homocysteine modulates 5Lipoxgenase expression level via DNA methylation. Aging Cell 2017; 16 (2 ), 273–280.27896923
21. Chu J , Li J-G , Joshi YB , Giannopoulos PF , Hoffman NE , Madesh M , Praticò D . Gamma secretase activating protein is a substrate for caspase-3: implications for Alzheimer’s disease. Biol. Psychiatry 2015; 77 (8 ): 720–728.25052851
22. Burd C , Cullen PJ . Retromer: a master conductor of endosome sorting. Cold Spring Harb. Persp. Biol 2014; 6 , a016774.
23. Trousdale C , Kim K . Retromer: Structure, function, and roles in mammalian disease. Eur. J. Cell Biol 2015; 94 (11 ):513–521.26220253
24. Wang S , Bellen HJ . The retromer complex in development and disease. Development 2015; 142 , 2392–2396.26199408
25. Vagnozzi A , Praticò D . Endosomal sorting and trafficking, the retromer complex and neurodegeneration. Mol. Psychiatry 2018 8 17. doi: 10.1038/s41380-018-0221-3 . [Epub ahead of print]
26. Choy RW Retromer mediates a discrete route of local membrane delivery to dendrites. Neuron 2014; 82 ; 55–62.24698268
27. Kim E , Lee Y , Lee H-J , Kim JS , Song BS , Huh JW , Lee SR , Kim SU , Kim SH , Hong Y , Shim I , Chang KT . Implication of mouse Vps26b-Vps29-Vps35 retromer complex in sortilin trafficking. Biochem. Biophys. Res. Commun 2010; 403 :167–171.21040701
28. Lambert JC , Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nature Gen 2013; 45 ,1452–1458.
29. Puzzo D , Lee L , Palmeri A , Calabrese G , Arancio O . Behavioral assays with mouse models of Alzheimer’s disease: practical considerations and guidelines. Biochem Pharmacol 2014; 88 (4 ): 450–467.24462904
30. Whiting MD , Kokiko-Cochran ON . Assessment of cognitive function in the water maze task: maximizing data collection and analysis in animal models of brain injury. Methods Mol Biol 2016; 1462 : 553–71.27604738
31. Wang JZ , Xia YY , Grundke-Iqbal I , Iqbal K . Abnormal hyper-phosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J. Alzheim. Dis 2013; 33 (suppl. 1 ), S123–S139.
32. Henstridge CM , Pickett E , Spires-Jones TL . Synaptic pathology: A shared mechanism in neurological disease. Ageing Res. Rev 2016; 28 :72–84.27108053
33. Ondrejcak T , Klyubin I , Hu NW , Barry AE , Cullen WK , Rowan MJ . Alzheimer’s disease amyloid beta-protein and synaptic function. Neuromolecular Med 2010; 12 (1 ):13–26.19757208
34. Spangenberg EE , Green KN . Inflammation in Alzheimer’s disease: lessons learned from microglia-depletion models. Brain Behav. Immun 2017; 61 :1–11.27395435
35. Clayton KA , Van Enoo AA , Ikezu T . Alzheimer’s Disease: The role of microglia in brain homeostasis and proteopathy. Front. Neurosci 2017; 11 :680.29311768
36. González-Reyes RE , Nava-Mesa MO , Vargas-Sánchez K , Ariza-Salamanca D , Mora-Muñoz L . Involvement of astrocytes in Alzheimer’s disease from a neuroinflammatory and oxidative stress perspective. Front. Mol. Neurosci 2017; 10 :427.29311817
37. Chun H , Lee CJ . Reactive astrocytes in Alzheimer’s disease: A double-edged sword. Neurosci. Res 2018; 126 : 44–52.29225140
38. Williams ET , Chen X , Moore DJ . VPS35, the retromer complex and Parkinson’s disease. J Parkinsons Dis 2017;7 (2 ):219–233.28222538
39. Mecozzi VJ , Berman DE , Simoes S , Vetanovetz C , Awal MR , Patel VM , Schneider RT , Petsko GA , Ringe D , Small SA . Pharmacological chaperones stabilize retromer to limit APP processing. Nat Chem Biol 2014;10 (6 ):443–449.24747528
